News

Filter

GlaxoSmithKline returns Duchenne drug rights to Prosensa

GlaxoSmithKline returns Duchenne drug rights to Prosensa

13-01-2014

UK pharma giant GlaxoSmithKline says that its partner, Dutch biotech firm Prosensa has regained all rights…

BiotechnologydrisapersenGlaxoSmithKlineLicensingProsensaRare diseases

Sarepta plunges as FDA questions eteplirsen trial results

Sarepta plunges as FDA questions eteplirsen trial results

12-11-2013

Shares of US RNA-based drug developer Sarepta Therapeutics plummeted in pre-market trading on November…

BiotechnologydrisaperseneteplirsenGlaxoSmithKlineNorth AmericaRare diseasesRegulationResearchSarepta Therapeutics

Prosensa stock goes into free fall as drisapersen fails in Ph III study

23-09-2013

UK pharma giant GlaxoSmithKline and Netherlands-based partner Prosensa announced on Friday that GSK's…

drisaperseneteplirsenGlaxoSmithKlinePharmaceuticalProsensaRare diseasesResearchSarepta Therapeutics

Potential Duchenne drug expected to complete phase III trial this year

16-08-2013

Dutch biotech company Prosensa says it has made progress with its Duchenne treatments, with six exon…

drisapersenEuropeGeneticsGlaxoSmithKlinePharmaceuticalProsensaResearch

FDA backs Baxter's Rixubis for hemophilia B; Breakthrough status for GSK's drisapersen

28-06-2013

The US Food and Drug Administration yesterday (June 27) approved Baxter International's (NYSE: BAX) Rixubis…

Baxter InternationaldrisapersenGlaxoSmithKlineNorth AmericaPharmaceuticalRare diseasesRegulationRixubis

COMPANY SPOTLIGHT

Menarini

Back to top